The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

Blood

Volumn 106, Issue 4, 2005, Pages 1207-1209

  Steensma, David P ^b   Dewald, Gordon W ^b   Lasho, Terra L ^b   Powell, Heather L ^b   McClure, Rebecca F ^b   Levine, Ross L ^b   Gilliland, D Gary ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; HYPEREOSINOPHILIC SYNDROME; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SOMATIC MUTATION; SYSTEMIC MASTOCYTOSIS;

EID: 21344440357     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1183     Document Type: Article

References (24)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell. 2005;7:387-397.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;484:1144-1148.
4. Kralovics R, Passamonti F, Buser A, et al. Again-of-function mutation of Jak2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
5. Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc. 1998;73:1177-1184.
6. Tefferi A. Chronic myeloid disorders: classification and treatment overview. Semin Hematol. 2001;38:1-4.
7. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
8. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038-3045.
9. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535-536.
10. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
11. O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN101: tightening the grip of imatinib. Cancer Cell. 2005;7:117-119.
12. Sawyers CL, Shah NP, Kantarjian HM, et al. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study. Plenary session, 46th Annual Meeting of the American Society of Hematology. San Diego, CA: 2004.
13. Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2005;105:443-452.
14. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
15. Boultwood J, Wainscoat JS. Clonality in the myelodysplastic syndromes. Int J Hematol. 2001;73:411-415.
16. Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep. 2004;3:218-226.
17. Cortes J. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep. 2003;2:202-208.
18. Gonzalez-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I. Two groups of chronic myelomonocytic leukaemia, myelodysplastic and myeloproliferative: prognostic implications in a series of a single center. Leuk Res. 2002;26:821-824.
19. Nosslinger T, Reisner R, Gruner H, et al. Dysplastic versus proliferatlve CMML: a retrospective analysis of 91 patients from a single institution. Leuk Res. 2001;25:741-747.
20. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML: dysplastic versus proliferative type. Leuk Res. 1998;22:871-878.
21. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27:95-120.
22. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
23. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313-317.
24. Sandberg EM, Wallace TA, Godeny MD, Vonderlinden D, Sayeski PP. Jak2 tyrosine kinase: a true jak of all trades? Cell Biochem Biophys. 2004;41:207-232.